Noskapin Orifarm Healthcare (Noscapine Hydrochloride Monohydrate)

Noscapine modulates neuronal activity in the central cough centre, likely through interaction with sigma‑1 receptors and inhibition of calcium‑dependent excitability. This reduces the transmission of cough signals without affecting normal respiratory function, offering a non‑opioid approach to cough control.

The appropriate dose of Noskapin Orifarm Healthcare is determined by a qualified prescriber based on the patient’s age, weight, and clinical condition. Patients should follow the healthcare professional’s instructions and not exceed the recommended amount.

Safety data for noscapine in pregnancy and lactation are limited. Healthcare providers should evaluate the risk‑benefit ratio before prescribing to pregnant or nursing mothers, and use only if clearly needed and approved by the prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Noskapin (noscapine) is a non‑opioid antitussive, distinguishing it from opioid‑based cough medicines such as codeine. It offers cough relief with a lower risk of dependence and respiratory depression, though it may cause mild sedation. Its mechanism via sigma‑1 receptors differs from the central µ‑opioid receptor activity of opioid suppressants.

Store Noskapin Orifarm Healthcare below 25 °C in a dry environment. Keep the product in its original packaging to protect it from moisture and light. Do not store in extreme temperatures or humid conditions to maintain potency.

Noskapin Orifarm Healthcare is taken orally, typically as a tablet or capsule, with or without food as directed by the prescriber. Swallow the dosage form whole with water and avoid crushing or chewing unless specifically instructed.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, and neutropenia. Patients should seek immediate medical attention if they experience rash, difficulty breathing, jaundice, or unexplained fever while using the product.

Individuals with known hypersensitivity to noscapine or any excipients in the formulation should avoid the product. It is also contraindicated in patients taking multiple central cough suppressants or those with severe hepatic impairment without medical supervision.